Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 521

Sort by

Sort Order Select

Journal Articles

Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome

Amelia Ruffatti, Marta Tonello, Paolo Macor, Antonia Calligaro, Teresa Del Ross, Maria Favaro, Virginia Lotti, Antonio Carletto, Ariela Hoxha, Domenico Biasi

Blood (2021) 137 (21): 2989–2992.

https://doi.org/10.1182/blood.2020010575

Published: 2021

Journal Articles

A complementary new drug for PNH

Robert A. Brodsky

Blood (2020) 135 (12): 884–885.

https://doi.org/10.1182/blood.2020004959

Published: 2020

Journal Articles

Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS

Shruti Chaturvedi, Evan M. Braunstein, Xuan Yuan, Jia Yu, Alice Alexander, Hang Chen, Eleni Gavriilaki, Ravi Alluri, Michael B. Streiff, Michelle Petri, Mark A. Crowther, Keith R. McCrae, Robert A. Brodsky

Blood (2020) 135 (4): 239–251.

https://doi.org/10.1182/blood.2019003863

Published: 2020

Includes: Supplemental data

Journal Articles

Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological Data

Aleksandr Kulagin, Vadim Ptushkin, MD PhD Professor, Elena Lukina, MD PhD Professor, Elena Gapchenko, MD, Oksana Markova, MD MSc, Eugene Zuev, MD, Dmitry Kudlay, MD PhD Professor

Blood (2019) 134 (Supplement_1): 3748.

https://doi.org/10.1182/blood-2019-125693

Published: 2019

Journal Articles

No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient

Kyoung Ha Kim, MD PhD, Taehyung Kim, MSc, Jae-Sook Ahn, MD PhD, Zeyad Al-Shaibani, Arjun Law, MD, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Auro Viswabandya, MDDM, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Zhaolei Zhang, PhD, Tamir Biezuner, PhD, Liran I. Shlush, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 4514.

https://doi.org/10.1182/blood-2019-129497

Published: 2019

Journal Articles

Easix Is Strongly Associated with Complement Activation and Overall Survival in Adult Allogeneic Hematopoietic Cell Transplantation Recipients

Eleni Gavriilaki, MD, Ioanna Sakellari, Thomas Chatziconstantinou, Despina Mallouri, Ioannis Batsis, Anna Vardi, MD PhD, Zoi Bousiou, MD MSc, Evdoxia Koravou, Marianna Masmanidou, Tasoula Touloumenidou, Lila Papalexandri, MD, Anastasia Athanasiadou, MD, Evangelia Yannaki, MD, Achilles Anagnostopoulos

Blood (2019) 134 (Supplement_1): 4520.

https://doi.org/10.1182/blood-2019-125332

Published: 2019

Journal Articles

Fludarabine Melphalan Versus Fludarabine Treosulfan As Reduced Intensity Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplant - a Retrospective Analysis

Akanksha Chichra, DNB, Lingaraj Nayak, MDDM MDcal Oncology, Rushabh Kothari, MD DM MDcal Oncology, Siddhesh Arun Kalantri, MD, Avinash Bonda, MD DM, Anant Gokarn, MD, Sachin Punatar, MBBS,MDDM MDcal Oncology, Bhausaheb Bagal, MD DM, Sadhana Kannan, MSc, Libin J Mathew, Navin Khattry, MD DM MDcal Oncology

Blood (2019) 134 (Supplement_1): 4493.

https://doi.org/10.1182/blood-2019-128099

Published: 2019

Journal Articles

Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Thierry Guillaume, MD PhD, Pierre Peterlin, Sylvain Thepot, MD, Amandine Le Bourgeois, MD, Alice Garnier, MD, Sylvie François, MD, Corentin Orvain, Yannick Le Bris, PharmD, Clémentine Fronteau, PharmD, Patrice Chevallier, MD

Blood (2019) 134 (Supplement_1): 4555.

https://doi.org/10.1182/blood-2019-123402

Published: 2019

Journal Articles

Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less

Mohamad Sobh, PharmD, Lothar B. Huebsch, MD, Mitchell Sabloff, MSc,MDFRCPC, Jill Fulcher, MDPhDMRCPI FRCPath(UK), Sultan Altouri, MDFRCPC, Michael Kennah, MD, Elizabeth Drouin, MD, David S. Allan, MD FRCPC, MSc, Harold Atkins, MD, Grace Christou, MD, Pierre Villeneuve, MD PhD, Alexandre P.Blanchard, PhD, Kelsey Maclellan, Ranjeeta Mallick, PhD MSc, BSc, Nicole B. Laferriere, MD PhD, Sathish Gopalakrishnan, MD, Sita D. Bhella, MD, Natasha Kekre, MDFRCPC, Christopher Bredeson, MDFRCPC,MSc

Blood (2019) 134 (Supplement_1): 3263.

https://doi.org/10.1182/blood-2019-122436

Published: 2019

Journal Articles

NK CD56 bright CD16 neg reconstitution over Time (NK56-index) Significantly Impacts Long Term Outcome in Allogeneic Hematopoietic Stem Cell Transplantation

Dante Escorcio-Tavares, Vinicius Campos de Molla, MD, Elisa Y Kimura, Vergilio Colturato, MD, Maura V Ikoma, MD PhD, Victor Gottardello Zecchin, MD, Adriana Seber, MD, Nelson Hamerschlak, MD PhD, Vanderson Rocha, MD PhD, Yana Novis, MD, Mihoko Yamamoto, MD PhD, Marcio Nucci, MD PhD, Celso Arrais-Rodrigues, MD PhD, Matheus Vescovi Gonçalves, MD PhD

Blood (2019) 134 (Supplement_1): 3295.

https://doi.org/10.1182/blood-2019-128263

Published: 2019

Journal Articles

Post-Transplant Cyclophosphamide after Matched Sibling, Unrelated and Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Comparative Study of the ALWP EBMT

Jaime Sanz, MD PhD, Jaques-Emmanuel Galimard, Boris V Afanasyev, MD PhD professor, Emanuele Angelucci, MD, Fabio Ciceri, MD, Didier Blaise, MD PhD, Jan J Cornelissen, MD PhD, Ellen Meijer, MD PhD, José Luis Díez-Martín, MD PhD, Yener Koc, MD, Montserrat Rovira, Luca Castagna, MD, Bipin N. Savani, MD, Annalisa Ruggeri, MD, Mohamad Mohty, MD PhD, Arnon Nagler, MD MSc

Blood (2019) 134 (Supplement_1): 3274.

https://doi.org/10.1182/blood-2019-125859

Published: 2019

Journal Articles

Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes

Kalyan Nadiminti, Abhishek A Mangaonkar, MBBS, Kimberly J. Langer, D.N.P., C.N.P., Shakila P Khan, MD, Vilmarie Rodriguez, MD, Naseema Gangat, MBBS, Michelle A Elliott, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, Mark Litzow, MD, William J Hogan, MB, BCh, Saad S. Kenderian, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 3300.

https://doi.org/10.1182/blood-2019-121742

Published: 2019

Journal Articles

Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Study By the Chronic Malignancies Working Party of EBMT

Blood (2019) 134 (Supplement_1): 3335.

https://doi.org/10.1182/blood-2019-121820

Published: 2019

Journal Articles

Sexual Life, Fertility and Ovarian Function in Women after Allogeneic Hematopoietic Stem Cell Transplant

Forgeard Nathalie, Matthieu Jestin, Dominique Vexiau, Florian Chevillon, MD, Régis Peffault de Latour, MD PhD, Marie Robin, MD, Flore Sicre de Fontbrune, Alienor Xhaard, David Michonneau, Nicolas Boissel, MD PhD, Catherine Poirot, MD PhD, Nathalie Dhedin, MD

Blood (2019) 134 (Supplement_1): 3301.

https://doi.org/10.1182/blood-2019-127371

Published: 2019

Journal Articles

Incorporation of Thiotepa in a Reduced Intensity Conditioning Regimen Leads to Improved Engraftment after Stem Cell Transplant for Patients with Hemophagocytic Lymphohistiocytosis

Swati Naik, MBBS, Olive S. Eckstein, MD, Ghadir Sasa, MD, Robert A. Krance, MD, Carl E. Allen, MD PhD, Helen E. Heslop, MD DSc, Caridad A. Martinez, MD

Blood (2019) 134 (Supplement_1): 3273.

https://doi.org/10.1182/blood-2019-132120

Published: 2019

Journal Articles

Masp-2 Levels Following Allogeneic Hematopoietic Stem Cell Transplantation in Adults: Correlation with Development of a Thrombotic Microangiopathy and Implications for Therapy with Anti-Complement Agents

Jeffrey Laurence, MD, Koen Van Besien, MD PhD, Jasimuddin Ahamed, PhD, Sonia Elhadad, PhD

Blood (2019) 134 (Supplement_1): 3305.

https://doi.org/10.1182/blood-2019-130919

Published: 2019

Journal Articles

Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Myelogenous Leukemia: ALWP of the EBMT Study

Bhagirathbhai Dholaria, MBBS, Myriam Labopin, MD, Emanuele Angelucci, MD, Fabio Ciceri, MD, José Luis Díez-Martín, MD PhD, Benedetto Bruno, MD, Simona Sica, MD, Yener Koc, MD, Zafer Gulbas, MD, Christoph Schmid, MD, Didier Blaise, MD PhD, Angelo Michele Carella, Giuseppe Visani, Bipin N. Savani, MD, Arnon Nagler, MD MSc, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 4584.

https://doi.org/10.1182/blood-2019-122279

Published: 2019

Journal Articles

Unmanipulated Haploidentical Transplant Followed By Post-Transplant Cyclophosphamide and Selective Ex Vivo T-Cell Depleted Haploidentical Transplant Results in Comparable Outcome As Unrelated Cord Blood Transplant for Adults with Haematological Malignancies- a Multicenter Study in Singapore

Cheryl XQ Lim, MBBS,MRCP, Yeh Ching Linn, MBBS, MRCP, Yin Jie Koh, Michelle Poon, MBBS, MRCP, FRCPATH, Aloysius YL Ho, MBBS,FRCP,FRCPath, William YK Hwang, MBBS, FRCP, Lip Kun Tan, MBBS, FRCP, FRCPath, Liang Piu Koh, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 4588.

https://doi.org/10.1182/blood-2019-125261

Published: 2019

Journal Articles

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Maria Queralt Salas, MD, Shiyi Chen, Wilson Lam, MD, David Loach, MD, Fotios V. Michelis, MD PhD, Zeyad Al-Shaibani, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM, Rajat Kumar, MD, Jonas Mattsson, MD, Arjun Law, MDDM

Blood (2019) 134 (Supplement_1): 4590.

https://doi.org/10.1182/blood-2019-126236

Published: 2019

Journal Articles

Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies

Margaux Damge, Sabine Furst, MD, Bénédicte Devictor, Samia Harbi, MD, Joseph Ciccolini, Angela Granata, MD, Thomas Pagliardini, MD, Boris Calmels, Pharm.D., Claude Lemarie, Pharm.D., Luca Castagna, MD, Valerio Maisano, MD, Faezeh Legrand, MD, Anne-Marie Stoppa, MD, Reda Bouabdallah, Evelyne D'Incan, Norbert Vey, MD PhD, Christian Chabannon, MD PhD, Didier Blaise, MD PhD, Raynier Devillier, MD PhD

Blood (2019) 134 (Supplement_1): 4503.

https://doi.org/10.1182/blood-2019-125994

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome

A complementary new drug for PNH

Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS

Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological Data

No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient

Easix Is Strongly Associated with Complement Activation and Overall Survival in Adult Allogeneic Hematopoietic Cell Transplantation Recipients

Fludarabine Melphalan Versus Fludarabine Treosulfan As Reduced Intensity Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplant - a Retrospective Analysis

Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less

NK CD56 bright CD16 neg reconstitution over Time (NK56-index) Significantly Impacts Long Term Outcome in Allogeneic Hematopoietic Stem Cell Transplantation

Post-Transplant Cyclophosphamide after Matched Sibling, Unrelated and Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Comparative Study of the ALWP EBMT

Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes

Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Study By the Chronic Malignancies Working Party of EBMT

Sexual Life, Fertility and Ovarian Function in Women after Allogeneic Hematopoietic Stem Cell Transplant

Incorporation of Thiotepa in a Reduced Intensity Conditioning Regimen Leads to Improved Engraftment after Stem Cell Transplant for Patients with Hemophagocytic Lymphohistiocytosis

Masp-2 Levels Following Allogeneic Hematopoietic Stem Cell Transplantation in Adults: Correlation with Development of a Thrombotic Microangiopathy and Implications for Therapy with Anti-Complement Agents

Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Myelogenous Leukemia: ALWP of the EBMT Study

Unmanipulated Haploidentical Transplant Followed By Post-Transplant Cyclophosphamide and Selective Ex Vivo T-Cell Depleted Haploidentical Transplant Results in Comparable Outcome As Unrelated Cord Blood Transplant for Adults with Haematological Malignancies- a Multicenter Study in Singapore

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only